Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rezolute in a report issued on Thursday, February 13th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute's Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.
Several other brokerages have also commented on RZLT. JMP Securities boosted their price target on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research note on Thursday, February 13th. Craig Hallum upgraded Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Guggenheim restated a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Finally, Wedbush restated an "outperform" rating and set a $112.00 price objective on shares of Rezolute in a research report on Monday, November 4th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $24.38.
Get Our Latest Stock Report on Rezolute
Rezolute Trading Up 1.8 %
Shares of NASDAQ:RZLT traded up $0.08 during trading on Monday, hitting $4.63. 337,775 shares of the stock were exchanged, compared to its average volume of 529,148. The company has a fifty day moving average price of $4.84 and a two-hundred day moving average price of $4.90. The company has a market cap of $280.28 million, a PE ratio of -3.80 and a beta of 1.10. Rezolute has a 12-month low of $1.45 and a 12-month high of $6.19.
Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11.
Insider Buying and Selling at Rezolute
In other Rezolute news, CFO Daron Evans purchased 9,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $4.60 per share, for a total transaction of $41,400.00. Following the acquisition, the chief financial officer now owns 140,900 shares of the company's stock, valued at approximately $648,140. The trade was a 6.82 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 18.39% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its holdings in shares of Rezolute by 699.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock worth $12,377,000 after buying an additional 2,210,038 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Rezolute by 2,817.1% during the 4th quarter. Woodline Partners LP now owns 1,089,345 shares of the company's stock worth $5,338,000 after buying an additional 1,052,002 shares during the last quarter. Susquehanna International Group LLP increased its holdings in shares of Rezolute by 749.0% during the 4th quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock worth $4,379,000 after buying an additional 788,349 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Rezolute during the 4th quarter worth $2,408,000. Finally, Nantahala Capital Management LLC increased its holdings in shares of Rezolute by 10.9% during the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock worth $14,004,000 after buying an additional 280,861 shares during the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.
Rezolute Company Profile
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
See Also
Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
